Rising incidence of hepatocellular carcinoma in the United States

New England Journal of Medicine

Volumn 340, Issue 10, 1999, Pages 745-750

  El Serag, Hashem B ^a,b   Mason, Andrew C ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; FEMALE; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 0033545541     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903113401001     Document Type: Article

References (29)

1. Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenger MH, Scharschmidt BF, eds. Sleisenger & Fordtran's gastrointestinal and liver disease: pathology/diagnosis/management. 6th ed. Vol. 1. Philadelphia: W.B. Saunders, 1998:1364-87.
2. Godley PA, Sandler RS. Liver cancer. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. Washington, D.C.: Government Printing Office, 1994:227-41. (NIH publication no. 94-1447.)
3. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-72.
4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350: 1142-3.
5. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214-5.
6. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29. [Erratum, CA Cancer J Clin 1998;48:192.]
7. Surveillance, Epidemiology, and End Results (SEER) program public-use CD-ROM (1973-1995). Bethesda, Md.: National Cancer Institute, April 1998 (software).
8. Department of Health and Human Services. The international classification of diseases, 9th rev., clinical modification: ICD-9 CM. 3rd ed. Vol. I. Diseases: tabular list. Washington, D.C.: Government Printing Office, March 1989. (DHHS publication no. (PHS) 89-1260.)
9. Percy C, Van Holten V, Muir C, eds. International classification of diseases for oncology. 2nd ed. Geneva: World Health Organization, 1990.
10. Grant BF, Zobeck T. Liver cirrhosis mortality in the United States, 1972-1986. Surveillance report no. 11. Rockville, Md.: National Institute on Alcohol Abuse and Alcoholism, 1989.
11. Kahn HA, Sempos CT. Statistical methods in epidemiology. Vol. 12 of Monographs in epidemiology and biostatistics. New York: Oxford University Press, 1989:87-95.
12. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987:58-61. (IARC scientific publications no. 82.)
13. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
14. Dufour MC. Chronic liver disease and cirrhosis. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. Washington, D.C.: Government Printing Office, 1994:615-46. (NIH publication no. 94-1447.)
15. Grant BF, Zobeck TS, Pickering RP. Liver cirrhosis mortality in the United States, 1973-1978. Rockville, Md.: National Institute on Alcohol Abuse and Alcoholism, 1990.
16. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994;35:828-32.
17. Yarrish RL, Werner BG, Blumberg BS. Association of hepatitis B virus infection with hepatocellular carcinoma in American patients. Int J Cancer 1980;26:711-5.
18. Castells L, Vargas V, Gonzalez A, Esteban J, Esteban R, Guardia J. Long interval between HCV infection and the development of hepatocellular carcinoma. Liver 1995;15:159-63.
19. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:Suppl 1: 62S-65S.
20. McQuillan GM, Alter MJ, Everhart JE. Viral hepatitis. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. Washington, D.C.: Government Printing Office, 1994:127-56. (NIH publication no. 94-1447.)
21. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992;326:1399-404.
22. McQuillan GM, Townsend TR, Fields HA, Carroll M, Leahy M, Polk BF. Seroepidemiology of hepatitis B virus infection in the United States: 1976 to 1980. Am J Med 1989;87:Suppl 3A:5S-10S.
23. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:Suppl 1:34S-38S.
24. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
25. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference: hepatocellular carcinoma. Ann Intern Med 1988; 108:390-401.
26. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
27. Serfaty L, Aumaitre H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-40.
28. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
29. Wong JB, Koff RS, Tinè F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.